Previous Close | 3.4300 |
Open | 3.4700 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 800 |
Day's Range | 3.4100 - 3.5900 |
52 Week Range | 2.0200 - 7.2000 |
Volume | |
Avg. Volume | 1,172,879 |
Market Cap | 279.299M |
Beta (5Y Monthly) | 1.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7060 |
Earnings Date | Apr 26, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.56 |
Every investor in Viking Therapeutics, Inc. ( NASDAQ:VKTX ) should be aware of the most powerful shareholder groups...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.
Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 27, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones.